Rather, our data suggest that in a setting of nonobese diet-induced MASLD, the beneficial effects of phosphatidylcholine may be related predominantly to a counterregulation of LPS–TLR4–PPARγ2–NFκB–dependent proinflammatory responses in the liver. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.